Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
Status:
Recruiting
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
This research is being done to find out if an investigational drug, Nivolumab, can be safely
administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the
investigational drug will help to prevent or delay relapse or progression of sarcomas. In
this study investigators will also be trying to learn more about how the investigational drug
changes blood and/or tumors. Participants are eligible for this trial if they have recently
undergone a "half-matched" (haplo) bone marrow transplant and have either relapsed or are at
high risk to relapse.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins